Home » Stocks » AKBA

Akebia Therapeutics, Inc. (AKBA)

Stock Price: $3.08 USD 0.02 (0.65%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $3.10 +0.02 (0.65%) Dec 4, 7:41 PM

AKBA Stock Price Chart

Key Info

Market Cap 445.18M
Revenue (ttm) 308.16M
Net Income (ttm) -390.94M
Shares Out 143.31M
EPS (ttm) -2.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $3.08
Previous Close $3.06
Change ($) 0.02
Change (%) 0.65%
Day's Open 3.10
Day's Range 3.01 - 3.11
Day's Volume 3,253,659
52-Week Range 2.22 - 13.58

AKBA Stock News

PRNewsWire - 2 days ago

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

PRNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

PRNewsWire - 2 weeks ago

CAMBRIDGE, Mass., Nov. 16, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

Zacks Investment Research - 3 weeks ago

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Seeking Alpha - 4 weeks ago

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 weeks ago

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

Zacks Investment Research - 1 month ago

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 23, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced the presentation of clinical data from its PRO2TECT global Phase 3 program that evalua...

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced the presentation of clinical data from its global INNO2VATE Phase 3 program, which demo...

GuruFocus - 1 month ago

Baupost Group leader Seth Klarman (Trades, Portfolio) disclosed earlier this week he divested of his position in Akebia Therapeutics Inc. (NASDAQ:AKBA).

Zacks Investment Research - 1 month ago

Akebia Therapeutics (AKBA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

PRNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 9, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that it will present data from its global Phase 3 programs of vadadustat for the treatm...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Zacks Investment Research - 3 months ago

Akebia (AKBA) posts top-line data from two phase III studies, namely PRO2TECT, which are evaluating vadadustat for treating anemia due to chronic kidney disease in adults not on dialysis. Shar...

24/7 Wall Street - 3 months ago

On Thursday, Akebia Therapeutics Inc. (NASDAQ: AKBA) announced topline results from the Phase 3 PRO2TECT studies evaluating the safety and efficacy of vadadustat in chronic kidney disease (CKD).

The Motley Fool - 3 months ago

The company's lead pipeline candidate fell short in a late-stage clinical study.

PRNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc.

Zacks Investment Research - 3 months ago

Investors need to pay close attention to Akebia (AKBA) stock based on the movements in the options market lately.

Zacks Investment Research - 3 months ago

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 3 months ago

CAMBRIDGE, Mass., Aug. 10, 2020 /PRNewswire/ -- Top-line data readout of global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to CKD in adult patients not on dialysis on t...

PRNewsWire - 4 months ago

CAMBRIDGE, Mass., Aug. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc.

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., June 29, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease...

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., June 18, 2020 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney dise...

Zacks Investment Research - 5 months ago

Is (AKBA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 5 months ago

Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PRNewsWire - 5 months ago

CAMBRIDGE, Mass., June 10, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

PRNewsWire - 6 months ago

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

PRNewsWire - 6 months ago

CAMBRIDGE, Mass., May 19, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).

Zacks Investment Research - 6 months ago

Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GuruFocus - 6 months ago

Akebia Therapeutics, Inc. (AKBA) is vying with several other pharma companies to bring potentially game-changing treatments for kidney dialysis patients.

Seeking Alpha - 6 months ago

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 6 months ago

The biotech reported great news for its lead pipeline candidate.

Zacks Investment Research - 6 months ago

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 25.40% and 14.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the s...

Benzinga - 6 months ago

Shares of Akebia Therapeutics (NASDAQ:AKBA) surged 24% after the company reported Q1 results.

Market Watch - 6 months ago

Shares of Akebia Therapeutics Inc. gained 30% in premarket trading on Tuesday after the drugmaker reported positive topline results from a Phase 3 trial for patients with chronic kidney disease.

The Motley Fool - 7 months ago

Akebia Therapeutics and Satsuma Pharmaceuticals could both be big winners for early shareholders.

Other stocks mentioned: STSA
Zacks Investment Research - 8 months ago

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

The Motley Fool - 8 months ago

The biotech provided a disappointing Q4 update.

Seeking Alpha - 8 months ago

Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -35.56% and -27.09%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for ...

Zacks Investment Research - 9 months ago

Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 10 months ago

I like Akebia at least for a 'watch item' position.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

The Motley Fool - 1 year ago

Momentum is continuing for the biotech after an announcement of positive clinical results and buying by key insiders earlier this month.

InvestorPlace - 1 year ago

For investors seeking out the ultimate high-risk, high-reward stocks, look no further than the biotech industry.

Other stocks mentioned: AERI, CYTK, NVAX, TBIO
Seeking Alpha - 1 year ago

Akebia Therapeutics: Vadadustat Approval Seems Make Or Break

The Motley Fool - 1 year ago

Insider buying is generating enthusiasm for this biotech stock among investors who aren't insiders.

Seeking Alpha - 1 year ago

Akebia Therapeutics: No Change To The Thesis, And The Lower Entry Point Improves The Bet

About AKBA

Akebia Therapeutics, a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agree... [Read more...]

Industry
Biotechnology
IPO Date
Mar 20, 2014
CEO
John Butler
Employees
358
Stock Exchange
NASDAQ
Ticker Symbol
AKBA
Full Company Profile

Financial Performance

In 2019, AKBA's revenue was $335.00 million, an increase of 61.26% compared to the previous year's $207.74 million. Losses were -$279.66 million, 94.8% more than in 2018.

Financial Statements